RLP 068
Alternative Names: RLP068; RLP068/Cl; VULNOFAST; VULNOFAST Gel; VULNOFAST PlusLatest Information Update: 21 Jul 2015
Price :
$50 *
At a glance
- Originator Molteni Therapeutics
- Class Antibacterials; Antifungals; Phthalocyanines; Small molecules
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Skin ulcer; Wound infections
Most Recent Events
- 27 Jul 2010 Phase-II clinical trials in Wound infections in Italy (Topical)
- 27 Aug 2007 Preclinical development is ongoing
- 27 Aug 2007 Molteni Therapeutics seeks partnerships to further develop candidates from this research programme